Vision Capital Advisors

CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

Meru Networks specializes in the development and marketing of wireless LAN infrastructure solutions that leverage virtualization to provide robust wireless services for critical business applications, including voice, video, and data. Since its inception in 2003, the company has introduced its innovative virtual cell wireless architecture, distinguishing itself from traditional hub-based WLAN systems. Meru's products aim to deliver high levels of performance, reliability, security, and cost-effectiveness, previously associated only with wired networking environments, thereby enabling enterprises to effectively manage their wireless networking needs.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate, vecabrutinib, is a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK) currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. Additionally, Sunesis is advancing SNS-510, which is in preclinical studies for various tumor types, alongside partnered programs such as TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer quinolone derivative. The company has established collaborations, including an agreement with Biogen Idec MA, Inc. for small molecule BTK inhibitors and a licensing agreement with Takeda Pharmaceutical Company Limited for preclinical PDK1 inhibitors. Founded in 1998 and headquartered in South San Francisco, California, Sunesis Pharmaceuticals is committed to innovative approaches in the ongoing fight against cancer.

OnlineSheetMusic is a licensed Internet-based digital sheet music stores. OSM offers nearly 140,000 pieces of digital sheet music and guitar tablature, many transposable instantly using its Solero software. Its titles are obtained from scores of publishers including: Alfred Music Publishing, Sony/ATV Music Publishing, Universal Music Publishing, EMI Music Publishing, BMG, Peer Music Publishing, and Disney Music Publishing.

MetricStream, Inc. is a leading provider of governance, risk, and compliance (GRC) software solutions, offering both cloud-based and on-premise applications. Founded in 1999 and headquartered in Palo Alto, California, the company serves a diverse range of industries, including banking, healthcare, automotive, and energy. Its software platform encompasses various functions such as internal audits, regulatory compliance, risk management, quality assurance, and vendor governance, enabling organizations to enhance their business performance and make informed decisions amidst regulatory complexities. MetricStream's solutions facilitate the integration of governance, risk management, and compliance across organizations, empowering users to navigate risks effectively while pursuing growth opportunities. With a commitment to customer support, implementation, and training, MetricStream continues to strengthen its presence in the global market through strategic partnerships and a robust portfolio of services.